Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12533352 | 0.83 | P2RX7 (0.31) | P2RX7GABRA1GABRB1 | |
| SCHEMBL23432951 | 0.82 | EIF4A3 (0.36) | EIF4A3P2RX7GABRA1GABRB1 | |
| SCHEMBL22483859 | 0.80 | KDM1A (0.35) | EIF4A3GABRA1GABRB1 | |
| SCHEMBL21567158 | 0.78 | CYP3A4 (0.38) | EIF4A3GABRA1GABRB1 | |
| SCHEMBL12599943 | 0.78 | GABRA1 (0.37) | EIF4A3GABRA1GABRB1 | |
| SCHEMBL31387648 | 0.77 | CXCL8 (0.38) | — | |
| SCHEMBL17517184 | 0.77 | LMNA (0.35) | EIF4A3GABRA1GABRB1 | |
| SCHEMBL20711666 | 0.75 | LMNA (0.41) | EIF4A3GABRA1GABRB1 | |
| SCHEMBL12173269 | 0.74 | EIF4A3 (0.41) | EIF4A3GABRA1GABRB1 | |
| SCHEMBL12533397 | 0.72 | TRPA1 (0.33) | EIF4A3GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2022208391-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC, (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2020198266-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | EIF4A3 1685/4885P2RX7 3336/4885GABRA1 4842/4885 |
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | EIF4A3 1685/4885P2RX7 3336/4885GABRA1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.